V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330003250 | 330006907 | 1.56 | null | Palliative (P) | 2017-09-05 | 2017-09-05 | DOXORUBICIN | N | N | 330012467 | DOXORUBICIN |
| 330003251 | 330001696 | 1.62 | 75 | Curative (C) | 2017-05-13 | 2017-05-21 | Carboplatin + Etoposide IV 3 day | 02 | N | 330012476 | CARBOPLATIN + ETOPOSIDE |
| 330003252 | 330001697 | 1.8 | 73.3 | Disease modification (D) | null | 2014-01-03 | BENDAMUSTINE + RITUXIMAB | null | null | 330012478 | BENDAMUSTINE + RITUXIMAB |
| 330003253 | 330001697 | 1.64 | null | Adjuvant (A) | 2015-01-26 | 2015-01-27 | Carboplatin + Paclitaxel (weekly) | 02 | N | 330012478 | CARBOPLATIN + PACLITAXEL |
| 330003254 | 330001697 | 1.83 | 90 | Neo-adjuvant (N) | 2016-12-01 | 2016-12-09 | Cisplatin + Doxorubicin | Y | N | 330012478 | CISPLATIN + DOXORUBICIN |
| 330003255 | 330001697 | 1.48 | 69.9 | null | 2015-03-25 | 2015-04-09 | BENDAMUSTINE + RITUXIMAB | N | N | 330012478 | BENDAMUSTINE + RITUXIMAB |
| 330003256 | 330001697 | null | 116.4 | Disease modification (D) | null | 2015-07-07 | BENDAMUSTINE + RITUXIMAB | null | null | 330012478 | BENDAMUSTINE + RITUXIMAB |
| 330003257 | 330001697 | 1.86 | 93 | Palliative (P) | 2017-05-24 | 2017-05-29 | Liposomal Doxorubicin (20mg/m2) | N | N | 330012478 | LIPOSOMAL DOXORUBICIN |
| 330003258 | 330001697 | 1.41 | 91.6 | null | 2016-05-04 | 2016-05-05 | BENDAMUSTINE + RITUXIMAB | N | N | 330012478 | BENDAMUSTINE + RITUXIMAB |
| 330003259 | 330001698 | 1.55 | 67 | Adjuvant (A) | 2016-08-29 | 2016-09-02 | Doxorubicin 75mg/m2 | 2 | N | 330012487 | DOXORUBICIN |
| 330003260 | 330001698 | 1.78 | 85.8 | 4 | 2018-01-08 | 2018-01-28 | Carboplatin + Paclitaxel (3 weekly) | N | N | 330012487 | CARBOPLATIN + PACLITAXEL |
| 330003261 | 330009729 | 1.58 | 71.5 | Curative (C) | 2015-06-09 | 2015-07-29 | CARBOPLATIN + ETOPOSIDE | 02 | N | 330012490 | CARBOPLATIN + ETOPOSIDE |
| 330003262 | 330009729 | 1.85 | 78.9 | Curative (C) | null | 2016-10-18 | Cisplatin + Doxorubicin | null | null | 330012490 | CISPLATIN + DOXORUBICIN |
| 330003263 | 330009729 | 1.75 | 34.9 | Disease modification (D) | 2016-02-12 | 2016-02-23 | BENDAMUSTINE + RITUXIMAB | 2 | N | 330012490 | BENDAMUSTINE + RITUXIMAB |
| 330003264 | 330009729 | 1.71 | 52 | Neo-adjuvant (N) | 2014-09-12 | 2014-09-21 | Cisplatin + Etoposide (3 day) | N | N | 330012490 | CISPLATIN + ETOPOSIDE |
| 330003265 | 330009729 | 1.81 | 61.8 | Adjuvant (A) | null | 2014-10-22 | CETUXIMAB + RT | null | null | 330012490 | CETUXIMAB + RT |
| 330003266 | 330001699 | null | 102 | Curative (C) | 2013-12-19 | 2013-12-19 | OST Euramos 1 Closed Trial - AP | N | N | 330012502 | MAP |
| 330003267 | 330001699 | 1.85 | 76 | Not known (9) | 2014-04-02 | 2014-04-03 | CVP R | N | N | 330012502 | CVP R |
| 330003268 | 330001700 | null | 86.2 | Disease modification (D) | 2013-11-12 | 2013-11-16 | CVP R | N | N | 330012504 | CVP R |
| 330003269 | 330001700 | 1.57 | 72.5 | Curative (C) | 2017-12-31 | 2018-01-01 | OST Euramos 1 Closed Trial - AP | N | null | 330012504 | MAP |
| 330003270 | 330001700 | 0 | 47.9 | Neo-adjuvant (N) | 2014-10-12 | 2014-10-13 | PAM x 2 post-surgery (cycles 3&4) | Y | N | 330012504 | MAP |
| 330003271 | 330001701 | 1.66 | 59.7 | Palliative (P) | 2014-02-01 | 2014-02-05 | CISPLATIN + GEMCITABINE | Y | N | 330012514 | CISPLATIN + GEMCITABINE |
| 330003272 | 330001702 | 1.85 | 76.6 | Curative (C) | 2013-06-29 | 2013-07-30 | CETUXIMAB | N | Y | 330012515 | CETUXIMAB |
| 330003273 | 330001703 | 1.73 | 69.5 | Curative (C) | 2014-08-23 | 2014-08-25 | CVP R | Y | N | 330012517 | CVP R |
| 330003274 | 330001703 | 1.59 | null | Neo-adjuvant (N) | 2015-04-12 | 2015-04-12 | EURAMOS TRIAL | N | N | 330012517 | EURAMOS TRIAL |
| 330003275 | 330009731 | 1.8 | 88.3 | Palliative (P) | 2013-07-18 | 2013-07-28 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 330012519 | CISPLATIN + GEMCITABINE |
| 330003276 | 330011296 | 1.68 | 102 | Neo-adjuvant (N) | 2013-07-19 | 2013-07-31 | Carbo F | N | N | 330012523 | CARBO + FLUOROURACIL |
| 330003277 | 330001704 | 1.83 | 112 | Palliative (P) | 2016-06-01 | 2016-06-01 | CISPLATIN + ETOPOSIDE | 02 | null | 330012524 | CISPLATIN + ETOPOSIDE |
| 330003278 | 330001705 | 0 | 58.4 | Neo-adjuvant (N) | 2017-08-26 | 2017-08-30 | Carboplatin+Fluorouracil 4 or 5 day | Y | N | 330012529 | CARBO + FLUOROURACIL |
| 330003279 | 330001706 | 1.53 | null | Curative (C) | 2014-07-05 | 2014-07-09 | DA 3 + 10 | N | N | 330012532 | DA |
| 330003280 | 330006913 | 1.81 | 80 | Neo-adjuvant (N) | 2013-02-13 | 2013-02-17 | Carbo F | 02 | N | 330012533 | CARBO + FLUOROURACIL |
| 330003281 | 330001707 | 1.65 | 44.6 | Neo-adjuvant (N) | 2013-03-14 | 2013-03-19 | GEMCARBO | N | N | 330012534 | GEMCARBO |
| 330003282 | 330001708 | 1.85 | 64.2 | Palliative (P) | null | 2015-10-01 | CAP | null | null | 330012535 | CAP |
| 330003283 | 330006914 | 1.86 | 112 | Curative (C) | 2017-07-25 | 2017-07-30 | EURAMOS TRIAL | null | N | 330012536 | EURAMOS TRIAL |
| 330003284 | 330001709 | 1.78 | 80.6 | Curative (C) | 2015-04-03 | 2015-04-13 | Dox + HD Mtx (post PAM) | N | N | 330012539 | DOXORUBICIN + HD MTX |
| 330003285 | 330001710 | 0 | 55 | Curative (C) | 2018-01-31 | 2018-02-09 | Carbo F | 2 | N | 330012540 | CARBO + FLUOROURACIL |
| 330003286 | 330001711 | 1.8 | 124.8 | Neo-adjuvant (N) | 2015-04-18 | 2015-04-18 | Dox + HD Mtx (post PAM) | N | N | 330012541 | DOXORUBICIN + HD MTX |
| 330003287 | 330001711 | 1.6 | 101 | Neo-adjuvant (N) | 2013-10-16 | 2013-10-22 | OST Euramos 1 Closed Trial - AP | Y | N | 330012541 | MAP |
| 330003288 | 330001712 | 1.79 | 78 | null | 2014-01-18 | 2014-01-18 | CISPLATIN + GEMCITABINE | 2 | N | 330012543 | CISPLATIN + GEMCITABINE |
| 330003289 | 330001713 | 0 | 37.6 | Curative (C) | 2016-02-10 | 2016-02-10 | CVP R | Y | N | 330012546 | CVP R |
| 330003290 | 330001714 | 1.82 | null | Curative (C) | 2014-06-05 | 2014-06-19 | DA | null | N | 330012547 | DA |
| 330003291 | 330001715 | 1.67 | null | Not known (9) | null | 2014-10-18 | CVP R | null | null | 330012549 | CVP R |
| 330003292 | 330001716 | 1.64 | 61.7 | Palliative (P) | 2015-06-01 | 2015-06-18 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 330012550 | CISPLATIN + GEMCITABINE |
| 330003293 | 330001716 | 1.8 | 63.4 | Curative (C) | 2016-02-05 | 2016-02-26 | CETUXIMAB | N | Y | 330012550 | CETUXIMAB |
| 330003294 | 330001716 | null | 76.3 | Curative (C) | 2017-12-02 | 2017-12-20 | DA 3 + 10 | N | N | 330012550 | DA |
| 330003295 | 330001717 | 1.68 | 63 | Palliative (P) | 2017-12-03 | 2017-12-14 | CAP | 02 | N | 330012554 | CAP |
| 330003296 | 330001718 | 1.72 | 62 | Palliative (P) | 2017-12-08 | 2017-12-21 | Cyclophosphamide + Dex + Rituximab | 2 | N | 330012557 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003297 | 330006917 | 1.85 | 57.9 | Curative (C) | 2015-12-23 | 2015-12-30 | GEMCARBO | N | N | 330012559 | GEMCARBO |
| 330003298 | 330001719 | 0 | 63 | Neo-adjuvant (N) | 2015-09-10 | 2015-09-19 | Dox + HD Mtx (post PAM) | N | N | 330012562 | DOXORUBICIN + HD MTX |
| 330003299 | 330001719 | 1.78 | 89.1 | Curative (C) | 2016-02-02 | 2016-02-14 | CETUXIMAB + RT | N | Y | 330012562 | CETUXIMAB + RT |